Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis, a clinical-stage biotechnology company focused on gene editing, has announced its participation in four upcoming investor conferences. These events include Citi's 17th Annual Biopharma Conference on September 7, 2022, and the Wells Fargo 2022 Healthcare Conference from September 7-9, followed by presentations at the Baird Global Healthcare Conference on September 13 and the Jefferies Cell and Genetic Medicine Summit on September 29. Cellectis is dedicated to developing innovative therapies for cancer and genetic diseases using its proprietary TALEN® technology and aims to provide treatment options for various cancers.
Cellectis announced its share and voting rights update as of July 31, 2022. The total number of ordinary shares in circulation stands at 45,510,810, with total voting rights reaching 51,875,672. This report is part of compliance with the French financial markets authority regulations.
As a leading clinical-stage biotechnology company, Cellectis is focused on developing innovative cell and gene therapies utilizing its gene-editing technology, TALEN®, and aims to address unmet medical needs in oncology.
Cellectis has received FDA clearance for its IND application for UCART20x22, targeting Non-Hodgkin Lymphoma. With a cash position of $135 million as of June 30, 2022, the company is well-positioned for upcoming clinical trials. Cellectis is progressing in enrolling patients in three Phase 1 trials and plans to initiate the NatHaLi-01 clinical trial this year. However, the company reported a significant drop in revenue, from $43 million in the first half of 2021 to $7 million in 2022, primarily due to decreased collaboration income.
Cellectis announced FDA clearance for its IND application to initiate a Phase 1/2a clinical trial of UCART20x22 in patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL). This marks the company's first allogeneic dual CAR T product, targeting CD20 and CD22 simultaneously. The NatHaLi-01 study is set to begin patient enrollment in the latter half of this year. UCART20x22 will utilize TALEN® technology to enhance patient outcomes in treating B-cell malignancies, potentially broadening the addressable patient population.
Cellectis (Nasdaq: CLLS) announced it will report Q2 financial results on August 4, 2022, after market close. A conference call to discuss these results is scheduled for August 5, 2022, at 8:00 AM EDT, providing updates on business activities. The company specializes in gene-editing technology for cancer therapies, utilizing its TALEN® system and PulseAgile platform. With 22 years of expertise, Cellectis aims to address unmet medical needs in oncology and other diseases.
Cellectis, a clinical-stage biotechnology company, announced the publication of research on its immune-evasive universal CAR T-cells in Nature Communications. The data suggests that these CAR T-cells can evade the host immune system, potentially improving treatment for multiple malignancies. The engineered cells demonstrated effectiveness against alloresponsive attacks, showing prolonged anti-tumor activity. Cellectis aims to make these therapies widely available, enhancing patient outcomes in difficult-to-treat cancers. The research indicates a promising advance towards universal CAR T-cell therapies.
Cellectis, a clinical-stage biotechnology company, announced the appointment of two new Directors, Axel-Sven Malkomes and Donald Bergstrom, M.D., Ph.D., during its annual shareholders meeting on June 28, 2022. Both appointees bring extensive experience from the healthcare and financial sectors. Dr. Bergstrom serves as Executive Vice President at Relay Therapeutics and has previous roles at Mersana Therapeutics and Sanofi Oncology. Mr. Malkomes has over 25 years in the industry, previously serving as CFO at Medigene AG and holding senior positions at Barclays and Société Générale.
Cellectis S.A. hosted its Annual Shareholders’ General Meeting on June 28, 2022, in Paris, France, with 67.23% of voting rights exercised.
Resolutions 1 through 23 and 25 were approved, while resolutions 24 and 26 were rejected. Detailed voting results are available on the company's website.
Cellectis is a clinical-stage biotech company focused on developing gene therapies for various cancers and blood disorders using its TALEN gene-editing technology and PulseAgile system.
Cellectis, a clinical-stage biotechnology company, focuses on gene-editing therapies for cancer and blood disorders. As of May 31, 2022, the company has 45,510,810 shares and 51,103,546 voting rights. Utilizing TALEN® gene editing technology, Cellectis aims to develop allogeneic CAR-T immunotherapies for conditions like acute myeloid leukemia and multiple myeloma. With over 22 years of expertise, it is dedicated to creating transformative therapies. The company is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis (Nasdaq: CLLS), a biotechnology firm focused on gene-editing therapies, will conduct its combined general meeting on June 28, 2022, at 2:30 p.m. CET in Paris. The meeting will cover key agenda items and participation details available on their website. Cellectis employs CAR-T immunotherapies and TALEN technology to develop treatments for various cancers and genetic disorders. With over 22 years of experience in gene editing, the company aims to deliver innovative therapies and remains dedicated to addressing unmet medical needs in oncology.
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?
How does Cellectis contribute to immuno-oncology?
